# Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)

> **NCT04358471** · PHASE2 · WITHDRAWN · sponsor: **Hemera Biosciences**

## Conditions studied

- Dry Age-related Macular Degeneration
- Geographic Atrophy
- Gene Therapy
- Intravitreal Injection

## Interventions

- **BIOLOGICAL:** Intravitreal AAVCAGsCD59
- **OTHER:** Intravitreal Sham Injection

## Key facts

- **NCT ID:** NCT04358471
- **Lead sponsor:** Hemera Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-07-31
- **Primary completion:** 2023-07-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The AAVCAGsCD59 asset has been transferred to Janssen Research and Development LLC
- **Last updated:** 2021-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358471, "Intravitreal AAVCAGsCD59 for Advanced Dry Age-related Macular Degeneration (AMD) With Geographic Atrophy (GA)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04358471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*